Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Dow Jones06-10

By Adria Calatayud

Sanofi said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy.

The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way.

The study termination deals an early setback to Sanofi's newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's Merck KGaA since 2021.

The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said.

The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms behind the disease.

The continuation of other studies with riliprubart, including another phase 3 trial for chronic inflammatory demyelinating polyneuropathy, will be evaluated in light of the data, Sanofi said.

The company said it doesn't expect to book any significant cost from the termination of the study, and that its guidance for 2026 remains unchanged.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

June 10, 2026 02:18 ET (06:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642448325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642448325","market":"sg","top_or_hot":-1,"title":"Sanofi to Stop Late-Stage Study of Immune-Disorder Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adria Calatayud \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy. \n</p>\n<p>\n  The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way. \n</p>\n<p>\n  The study termination deals an early setback to <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> since 2021. \n</p>\n<p>\n  The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said. \n</p>\n<p>\n  The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms behind the disease. \n</p>\n<p>\n  The continuation of other studies with riliprubart, including another phase 3 trial for chronic inflammatory demyelinating polyneuropathy, will be evaluated in light of the data, Sanofi said. \n</p>\n<p>\n  The company said it doesn't expect to book any significant cost from the termination of the study, and that its guidance for 2026 remains unchanged. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 02:18 ET (06:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi to Stop Late-Stage Study of Immune-Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi to Stop Late-Stage Study of Immune-Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-10 14:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adria Calatayud \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy. \n</p>\n<p>\n  The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way. \n</p>\n<p>\n  The study termination deals an early setback to <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> since 2021. \n</p>\n<p>\n  The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said. \n</p>\n<p>\n  The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms behind the disease. \n</p>\n<p>\n  The continuation of other studies with riliprubart, including another phase 3 trial for chronic inflammatory demyelinating polyneuropathy, will be evaluated in light of the data, Sanofi said. \n</p>\n<p>\n  The company said it doesn't expect to book any significant cost from the termination of the study, and that its guidance for 2026 remains unchanged. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 02:18 ET (06:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642448325","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642448325","pubTimestamp":1781072280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sanofi said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy.The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way.The study termination deals an early setback to Sanofi's newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's Merck KGaA since 2021.The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said.The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","BK4007":"制药"},"translate_title":"赛诺菲将停止免疫紊乱药物的后期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"By Adria Calatayud \n\n\n \n\n\nSanofi said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy. \n\n\n  The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way. \n\n\n  The study termination deals an early setback to Sanofi's newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's Merck KGaA since 2021. \n\n\n  The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said. \n\n\n  The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms behind the disease. \n\n\n  The continuation of other studies with riliprubart, including another phase 3 trial for chronic inflammatory demyelinating polyneuropathy, will be evaluated in light of the data, Sanofi said. \n\n\n  The company said it doesn't expect to book any significant cost from the termination of the study, and that its guidance for 2026 remains unchanged. \n\n\n \n\n\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 02:18 ET (06:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642448325","isCrawlerRequest":true}